Despite improvements in preventive and therapeutic strategies, acute graft-versus-host disease (aGvHD) remains a frequent complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). One attempt to prevent the development of aGvHD is the use of gut decontamination, i.e., eliminating the patient's intestinal microbiota by administering non-absorbable oral antibiotics. This approach was encouraged by murine studies in the 1970's which found that resident intestinal bacteria played a role in the pathogenesis of aGvHD and that eradicating these bacteria prevented severe aGvHD [1] . Subsequent cohort studies published in the 1990's reported that complete or more broad-spectrum gut decontamination lowered the incidence of aGvHD in both adult and paediatric patients undergoing allo-HSCT [2] [3] [4] [5] , leading to a wide practice of gut decontamination. However, since all studies were single-centre studies without a control group, later guidelines recommended that gut decontamination should generally not be offered [6] . Despite this, an informal survey of US transplant centres in a paper published last year [1] revealed that many still practice gut decontamination.
To examine the effect of gut decontamination on the development of aGvHD in patients transplanted in more recent years, we undertook a retrospective cohort study of all patients who underwent their first allo-HSCT at Rigshospitalet in Copenhagen, Denmark in the period from 1998-2007. This cohort represents 148 patients transplanted before September 2002 who received gut decontamination with 5.4 g cefuroxime, 540 mg tobramycin and 492 mg nystatin, given daily from 7 days before stem cell infusion (day -7) until engraftment, and 135 patients transplanted after September 2002 when we made a policy decision to withhold all gut decontamination. At this time, we initiated prophylactic i.v. ceftazidime during neutropenia instead of using empiric i.v. piperacillin for neutropenic fever. Routine preventive measures were also reduced from use of gloves and gowns to hand-washing only. All patients received myeloablative conditioning, and, as GvHD prophylaxis, oral cyclosporine 6.25 mg/kg twice daily from day -1 combined with short-course i.v. methotrexate on days 1 (15 mg/m 2 ), 3, 6 and 11 (10 mg/m 2 ). Cyclosporine was tapered to stop at day 180, unless GvHD was present.
We studied the retrospective cohort from day 0 until day +100. The primary outcome was the development of aGvHD grade II-IV, defined and graded according to standard criteria [7] , and secondary outcomes were the development of gut aGvHD stage II-IV and non-relapse mortality (NRM). Patient and transplantation characteristics of gut decontaminated and non-decontaminated patients were compared using chi-square test for categorical data and Wilcoxon rank-sum test for continuous data. Cumulative incidences of outcomes in gut decontaminated and nondecontaminated patients were compared using Gray's test treating relapse and death as competing risks for aGvHD outcomes and relapse as competing risk for the NRM outcome. To estimate hazard ratios (HR) for the associations between gut decontamination and the primary and secondary outcomes, we employed multivariate Cox proportional hazard regression models, censoring subjects at day +100, relapse and death (not the latter when NRM was the outcome), with the following a priori-defined covariates: patient age at transplantation, stem cell source, female donor to male recipient, donor relation and HLA matching, use of total body irradiation and use of anti-thymocyte globulin. Formal tests based on scaled Schoenfeld residuals were used to test the proportional hazards assumption for each model globally. All tests were two-sided with a statistical significance level of 0.05; no adjustment for multiple comparisons were made. All confidence intervals (CI) below are 95% CI. Statistical analyses were performed using R (version 3.4.2; R Foundation, Vienna, Austria) with survival and cmprsk libraries. Table 1 shows the patient and transplant characteristics of the gut decontaminated (n = 148) and nondecontaminated patients (n = 135) in the retrospective cohort. Gut decontaminated and non-decontaminated patients differed with regards to diagnosis, donor relation and HLA matching and stem cell source. Figure 1 shows the cumulative incidences of aGvHD grade II-IV, gut aGvHD stage II-IV and NRM during the first 100 days after transplant. For gut decontaminated patients, the cumulative incidences were 31% (CI: 24, 39%), 9% (CI: 4, 13%) and 10% (CI: 5, 15%), respectively. For non-decontaminated patients, the cumulative incidences were 23% (CI: 16, 30%), 4% (CI: 1, 7%) and 8% (4, 13%). Tests for differences in cumulative incidences between gut decontaminated and non-decontaminated patients returned p-values of 0.10, 0.08 and 0.60, respectively. In multivariate analysis (Supplementary Table 1 Our study found that gut decontaminated patients had a higher hazard of developing aGvHD grade II-IV following allo-HSCT than non-decontaminated patients. While statistical comparison of the difference in cumulative incidences of aGvHD grade II-IV (31 vs. 23% for gut , p-value = 0.02). This is likely due to an imbalance in the distribution of other risk factors for aGvHD as nondecontaminated patients, per study design, were transplanted in later years where the use of peripheral blood as stem cell source and HLA mismatched-transplants-both well-known risk factors for aGvHD-were more common, biasing an unadjusted comparison of the effect of gut decontamination towards the null. Secondary analysis of gut aGvHD stage II-IV indicated that the difference in hazard of aGvHD grade II-IV likely is driven by an increased hazard of gut aGvHD given the relatively large, yet only borderline significant, hazard ratio of 3.33 for gut decontaminated patients.
Our results are in agreement with a recent study from Canada which compared allo-HSCT patients transplanted between 2005 and 2012 at two different centres, with only one centre performing gut decontamination (by administering a fluoroquinolone) [8] . In this study, 42% of gut decontaminated patients developed aGvHD grade II-IV against 28% of non-decontaminated patients (p-value < 0.01), and the difference remained significant in multivariate analysis. The difference was driven by an increased incidence of aGvHD in the gut and the liver, and not in the skin, and overall 1-and 2-year survival rates were significantly lower in gut decontaminated patients. Interestingly, in a subgroup of myeloablative conditioned patients, which is the only type of patients included in our study, they found no difference in the rate of aGvHD, but overall 1-and 2-year survival rates were still significantly lower in gut decontaminated patients than in non-decontaminated patients.
The detrimental effect of gut decontamination is in accordance with recent research that has revealed associations between antibiotic-mediated disruption of the gut microbiota and aGvHD: Studies have shown that increased bacterial diversity following stem cell transplantation reduces GvHD-related mortality [9, 10] , especially when regarding abundance of bacteria from the genus Blautia [10] . Moreover, other studies have shown that cumulative antibiotic exposure and exposure to certain antibiotics (penicillin derivatives and carbapenems) increases the incidence of aGvHD [11] [12] [13] , and that a switch in the gut decontamination regimen from ciprofloxacin and metronidazole to rifaximin, an antibiotic that maintains commensal bacteria, was associated with less gut aGvHD-related mortality [14] . While our study, in which cefuroxime, tobramycin and nystatin comprised the decontamination regimen, corroborates that antibiotic use is associated with an increased hazard of aGvHD, we did not find any difference in NRM at day 100 between gut decontaminated and non-decontaminated patients, but this could very well be due to a lack of power and our chosen study period.
Our study has several limitations: First, this is a retrospective study using data from only a single transplant centre; second, we did not determine the degree of "success" of the gut decontamination by sampling stool cultures; and third, we cannot account for a hypothetical confounding of the association between gut decontamination and aGvHD by (an) other measure(s) of the policy change in infection prophylaxis as this could have altered the incidence of infections and/or later use of antibiotics and thus influence the subsequent risk of aGvHD [11, 12, 15] . Conversely, our study is strengthened by the inclusion of consecutive patients with reasonably similar patient and transplant characteristics, complete registration and follow-up of all patients in the study period and high quality of outcome data that were prospectively registered. Furthermore, our Gut decontamination and acute graft-versus-host diseasemethod of gut decontamination is the "complete" approach with administration of non-absorbable oral antibiotics and antifungals.
In conclusion, our study indicates that clinical employment of gut decontamination during allo-HSCT entails a higher hazard of developing aGvHD, supporting the current paradigm that low intestinal microbial diversity during allo-HSCT may lead to poorer outcomes. We thus reiterate that the practice of gut decontamination during allo-HSCT may be detrimental.
